APP
If any of the terms on this page are unclear or you want to learn more about them click here!
APP encodes the amyloid precursor protein, one of the most historically important molecules in Alzheimer’s research. Pathogenic APP variants can cause autosomal dominant early-onset familial Alzheimer’s disease, making APP one of the clearest genes linking disease to amyloid biology.
Normal function
APP is a membrane protein expressed in many tissues, including the brain. Its full normal role is still not completely known, but it appears to be involved in neuronal development, synaptic function, and cell signaling. Under normal processing conditions, APP can be cut in ways that do not generate toxic amyloid-beta species.
Mutation and effect
Pathogenic APP mutations alter how the protein is processed, often increasing the production of amyloid-beta or favoring forms that are more aggregation-prone, such as Aβ42. In some cases, APP duplication can also cause disease by increasing the amount of protein produced. This is a strong example of how changes in protein processing or protein amount can directly drive neurodegeneration.
Key mechanisms involved
The key mechanisms center on amyloid-beta overproduction and altered amyloid ratios, followed by plaque formation, synaptic dysfunction, and downstream tau pathology. There is also a robust immune response after plaque formation, which contributes to the sickness and death of neurons. APP is therefore one of the most direct genetic entry points into the amyloid cascade model of Alzheimer’s disease.
Implications for treatment
APP-related disease typically presents as early-onset Alzheimer’s disease, often decades earlier than the common sporadic form. It shares the core pathological hallmarks of Alzheimer’s, but the timing is much earlier, and the genetic cause is much more direct than in a lot of late-onset disease.
The discovery of APP’s involvement in Alzheimer’s helped establish the rationale for anti-amyloid therapies and continues to shape prevention-focused and early-intervention strategies. In families with known APP mutations, it also has implications for genetic counseling and biomarker-based pre-symptomatic research.
Research focus
Research on APP focuses on how different variants alter amyloid production, how amyloid changes interact with tau and inflammation, and how early in the disease process intervention must occur to be effective. APP remains central to understanding whether amyloid-directed treatment can truly alter disease trajectory.
Inheritance
APP causes a rare, inherited, early-onset form of Alzheimer's like that of PSEN1 and PSEN2 mutation. They account for about 15% of the families found to have this inherited form. The mutation is dominant, meaning one changed copy is enough to cause the disease. Almost everyone who carries the changed gene will develop symptoms eventually. Each child of a carrier has a 50/50 chance of inheriting it, and if they do, they'll very likely develop the disease themselves.
Sources
- Zhang, Y.-W., Thompson, R., Zhang, H., & Xu, H. (2011). APP processing in Alzheimer’s disease.
- Bateman, R. J., Xiong, C., Benzinger, T. L. S., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer’s disease.
- De Strooper, B., & Karran, E. (2016). The cellular phase of Alzheimer’s disease.
- MedlinePlus Genetics. APP gene.